News Lilly's appeal unlocks EU approval of Alzheimer's drug Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.
News KalVista bags FDA approval for delayed oral HAE drug KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.
R&D AI in clinical development & ‘white space’, with Andrew McKi... Andrew McKinnon, senior vice president and executive general manager at Medable, discussesleveraging AI to transform & accelerate clinical development
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.